An AI platform that screens patient charts for clinical trial eligibility increased randomization by 37.5% and cut screen ...

Synucleinopathies are a group of neurodegenerative disorders that include serious conditions such as Parkinson's disease and ...

Dr. Monty Pal summarizes his practical first-line treatment algorithm for advanced renal cell carcinoma (RCC), highlighting ...

The FDA has accepted Apnimed’s NDA for AD109 (aroxybutynin/atomoxetine), a potential first-in-class oral therapy for adults with obstructive sleep apnea.

The EGFR inhibitor for exon 20-mutated non-small cell lung cancer was developed by Shanghai-based Dizal and approved by the FDA last year.

New research from VCU Massey Comprehensive Cancer Center provides evidence for a combination treatment strategy that uses ...

Introduction Patients with chronic bronchitis suffer high morbidity and rapid functional decline; thus, novel treatments are ...

Older patients represent the fastest growing patient group in clinical care. They are a heterogeneous group, for whom evidence for making treatment decisions is often scarce. Important domains for ...

A network meta-analysis of nine randomized controlled trials found that once-weekly semaglutide showed the largest estimated ...

Polypharmacy in patients with cardiovascular disease occurs frequently across the age spectrum and can lead to inappropriate ...

Patients using GLP-1 RAs may experience dermatologic adverse side effects, including skin laxity, hair shedding, and facial ...

Discusses Progress in Sustainability Strategy and the Role of AI in Healthcare Innovation July 6, 2026 9:30 AM ...